Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918617 · ClinicalTrials.gov registry record · Phase 2
Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT02918617 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 203 participants.
The verdict
NCT02918617, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
This study will investigate the effectiveness of nanohydroxyapatite (nano-HAP)-containing toothpastes and cream to relieve dentin hypersensitivity, comparing it with those of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (Novamin® technology) and a standard fluoride dentifrice containing 1,500 ppm fluoride as sodium monofluorophosphate (MFP).
Interventions
- DRUG Control toothpaste containing Novamin® technology
- DRUG Control toothpaste containing 1500 ppm fluoride as MFP
- DRUG Test toothpaste with nano-HAP (high concentration)
- DRUG Test toothpaste with nano-HAP (low concentration)
- DRUG Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918617
The ClinicalTrials.gov registry entry for NCT02918617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Control toothpaste containing Novamin® technology is the first listed.
NCT02918617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918617 about?
NCT02918617 is a clinical study titled "Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream". This study will investigate the effectiveness of nanohydroxyapatite (nano-HAP)-containing toothpastes and cream to relieve dentin hypersensitivity, comparing it with those of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (Novamin® technology) and a standard fluoride...
What is the current status of trial NCT02918617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2015-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02918617?
The interventions under investigation include: Control toothpaste containing Novamin® technology (DRUG), Control toothpaste containing 1500 ppm fluoride as MFP (DRUG), Test toothpaste with nano-HAP (high concentration) (DRUG), Test toothpaste with nano-HAP (low concentration) (DRUG), Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3 (DRUG).
Who is sponsoring clinical trial NCT02918617?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.